Cargando…

Substrate utilisation of cultured skeletal muscle cells in patients with CFS

Chronic fatigue syndrome (CFS) patients often suffer from severe muscle pain and an inability to exercise due to muscle fatigue. It has previously been shown that CFS skeletal muscle cells have lower levels of ATP and have AMP-activated protein kinase dysfunction. This study outlines experiments loo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomas, Cara, Elson, Joanna L., Newton, Julia L., Walker, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588462/
https://www.ncbi.nlm.nih.gov/pubmed/33106563
http://dx.doi.org/10.1038/s41598-020-75406-w
_version_ 1783600377431588864
author Tomas, Cara
Elson, Joanna L.
Newton, Julia L.
Walker, Mark
author_facet Tomas, Cara
Elson, Joanna L.
Newton, Julia L.
Walker, Mark
author_sort Tomas, Cara
collection PubMed
description Chronic fatigue syndrome (CFS) patients often suffer from severe muscle pain and an inability to exercise due to muscle fatigue. It has previously been shown that CFS skeletal muscle cells have lower levels of ATP and have AMP-activated protein kinase dysfunction. This study outlines experiments looking at the utilisation of different substrates by skeletal muscle cells from CFS patients (n = 9) and healthy controls (n = 11) using extracellular flux analysis. Results show that CFS skeletal muscle cells are unable to utilise glucose to the same extent as healthy control cells. CFS skeletal muscle cells were shown to oxidise galactose and fatty acids normally, indicating that the bioenergetic dysfunction lies upstream of the TCA cycle. The dysfunction in glucose oxidation is similar to what has previously been shown in blood cells from CFS patients. The consistency of cellular bioenergetic dysfunction in different cell types supports the hypothesis that CFS is a systemic disease. The retention of bioenergetic defects in cultured cells indicates that there is a genetic or epigenetic component to the disease. This is the first study to use cells derived from skeletal muscle biopsies in CFS patients and healthy controls to look at cellular bioenergetic function in whole cells.
format Online
Article
Text
id pubmed-7588462
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75884622020-10-27 Substrate utilisation of cultured skeletal muscle cells in patients with CFS Tomas, Cara Elson, Joanna L. Newton, Julia L. Walker, Mark Sci Rep Article Chronic fatigue syndrome (CFS) patients often suffer from severe muscle pain and an inability to exercise due to muscle fatigue. It has previously been shown that CFS skeletal muscle cells have lower levels of ATP and have AMP-activated protein kinase dysfunction. This study outlines experiments looking at the utilisation of different substrates by skeletal muscle cells from CFS patients (n = 9) and healthy controls (n = 11) using extracellular flux analysis. Results show that CFS skeletal muscle cells are unable to utilise glucose to the same extent as healthy control cells. CFS skeletal muscle cells were shown to oxidise galactose and fatty acids normally, indicating that the bioenergetic dysfunction lies upstream of the TCA cycle. The dysfunction in glucose oxidation is similar to what has previously been shown in blood cells from CFS patients. The consistency of cellular bioenergetic dysfunction in different cell types supports the hypothesis that CFS is a systemic disease. The retention of bioenergetic defects in cultured cells indicates that there is a genetic or epigenetic component to the disease. This is the first study to use cells derived from skeletal muscle biopsies in CFS patients and healthy controls to look at cellular bioenergetic function in whole cells. Nature Publishing Group UK 2020-10-26 /pmc/articles/PMC7588462/ /pubmed/33106563 http://dx.doi.org/10.1038/s41598-020-75406-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Tomas, Cara
Elson, Joanna L.
Newton, Julia L.
Walker, Mark
Substrate utilisation of cultured skeletal muscle cells in patients with CFS
title Substrate utilisation of cultured skeletal muscle cells in patients with CFS
title_full Substrate utilisation of cultured skeletal muscle cells in patients with CFS
title_fullStr Substrate utilisation of cultured skeletal muscle cells in patients with CFS
title_full_unstemmed Substrate utilisation of cultured skeletal muscle cells in patients with CFS
title_short Substrate utilisation of cultured skeletal muscle cells in patients with CFS
title_sort substrate utilisation of cultured skeletal muscle cells in patients with cfs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588462/
https://www.ncbi.nlm.nih.gov/pubmed/33106563
http://dx.doi.org/10.1038/s41598-020-75406-w
work_keys_str_mv AT tomascara substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs
AT elsonjoannal substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs
AT newtonjulial substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs
AT walkermark substrateutilisationofculturedskeletalmusclecellsinpatientswithcfs